Tag: pipeline

MONACO, July 07, 2025 (GLOBE NEWSWIRE) -- Exploring the potential of alternative fuels in the maritime sector. During the days of the 12th Monaco Energy Boat Challenge (1-5 July), at the Alternative Fuels Conference on Friday morning, different actors gathered together to discuss technology aspects, challenges, and advancements related to marine energy solutions based on alternative fuels, including hydrogen, methanol, and other innovative sources. Clean hydrogen is still the starting point when it comes to clean energy sources, but now it is time to investigate more to make the next step. As of now, the technology is ready, but it has to be accompanied by infrastructure, investments and supply chain. From an infrastructure point of view, the evolution could be the same as it occurred with oil in the past. “We are looking at the full value chain, a bit like if it was a pipeline. We only provide one piece of the puzzle, but it is a big one. The ecosystem is made of a vessel that will transport, for example, green ammonia from Australia to Korea to Japan in bulk format. Basically, we help owners thanks to our expertise in owning and leasing large floating units,” said Philippe Lavagna, product account manager at SBM Offshore. “We say we need a transition, and it takes time. Miracles don't happen overnight. That's why we are committed to provide clean solutions to the industry,” he added.

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)

Webcast to be held Monday, July 7th at 8:00 a.m. ET

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sable Offshore Corp. (“Sable” or the “Company”) (NYSE: SOC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.’s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public.

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

München, Deutschland, 04. Juli 2025 – Das Komitee des Strüngmann Award gab heute bekannt, dass Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller, die Gründer von Araris Biotech, als die diesjährigen Preisträger ausgezeichnet wurden. Der Award verfolgt das Ziel, herausragende unternehmerische und wissenschaftliche Leistungen sowie bahnbrechende Ideen in der Life-Science-Branche zu fördern. Das Gründerteam von Araris Biotech überzeugte nicht nur durch die Entwicklung einer neuartigen Technologie im Bereich der Antikörper-Wirkstoff-Konjugate, sondern auch durch deren erfolgreiche Validierung in Form von Partnerschaften und einem präklinischen Exit. Diese neue Medikamentenklasse hat das Potenzial, maßgeblich zur Weiterentwicklung zielgerichteter Krebstherapien beizutragen und somit einen Mehrwert für Menschen mit Krebserkrankungen weltweit zu erreichen.